Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Multiple Myeloma Treatment Market, by Treatment
6.1 Introduction
6.2 Chemotherapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.1 Bendamustine (Treanda)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.2 Cyclophosphamide (Cytoxan)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.3 Doxorubicin (Adriamycin)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.4 Etoposide
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.5 Liposomal doxorubicin (Doxil)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.6 Melphalan (Alkeran, Evomela)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.7 Vincristine (Oncovin)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3 Corticosteroids
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.4 Interferon
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.5 Stem Cell Transplant
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.6 Radiation therapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 7. Global Multiple Myeloma Treatment Market, by End-User
7.1 Introduction
7.2 Hospitals
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3 Clinics
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.4 Independent Pharmacies
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.5 Other
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 8. Global Multiple Myeloma Treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
Chapter 10. Company Profiles
10.1 Celgene Corporation
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Janssen Biotech, Inc.
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Bristol-Myers Squibb Company
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Product Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Millennium Pharmaceuticals
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Amgen, Inc
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Genzyme Corporation
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Juno Therapeutics
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.7 Johnson & Johnson
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 F. Hoffmann-La Roche Ltd
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.11 GlaxoSmithKline plc
10.91 Overview
10.92 Product Overview
10.93 Financials
10.94 Key Developments
10.95 SWOT Analysis
10.10 AbbVie Inc
10.10.1 Overview
10.10.2 Product Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.13 Innate Pharma SA
10.13.1 Overview
10.13.2 Product Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Celldex Therapeutics, Inc
10.14.1 Overview
10.14.2 Product Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.15 Onyx Pharmaceuticals
10.15.1 Overview
10.15.2 Product Overview
10.15.3 Financials
10.15.4 Key Developments
10.15.5 SWOT Analysis
10.16 Pfizer
10.16.1 Overview
10.16.2 Product Overview
10.16.3 Financials
10.16.4 Key Developments
10.16.5 SWOT Analysis
10.17 Takeda Pharmaceuticals
10.17.1 Overview
10.17.2 Product Overview
10.17.3 Financials
10.17.4 Key Developments
10.17.5 SWOT Analysis
Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the Multiple Myeloma Treatment Market
Chapter 12. Appendix
LIST OF TABLES
Table 1 Global Multiple Myeloma Treatment Market Synopsis, 2020–2027
Table 2 Global Multiple Myeloma Treatment Market Estimates and Forecast, 2020–2027 (USD Million)
Table 3 Global Multiple Myeloma Treatment Market, by Region, 2020–2027 (USD Million)
Table 4 Global Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 5 Global Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 6 North America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 7 North America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 8 US: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 9 US: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 10 Canada: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 11 Canada: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 12 South America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 13 South America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 14 Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 15 Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 16 Western Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 17 Western Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 18 Eastern Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 19 Eastern Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 20 Asia-Pacific: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 21 Asia-Pacific: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 22 Middle East & Africa: Multiple Myeloma Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 23 Middle East & Africa: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Multiple Myeloma Treatment Market
Figure 3 Segmentation Market Dynamics for Global Multiple Myeloma Treatment Market
Figure 4 Global Multiple Myeloma Treatment Market Share, by Treatment, 2020
Figure 5 Global Multiple Myeloma Treatment Market Share, by End-User, 2020
Figure 6 Global Multiple Myeloma Treatment Market Share, by Region, 2020
Figure 7 North America: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 8 Europe: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 9 Asia-Pacific: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 10 Middle East & Africa: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 11 Global Multiple Myeloma Treatment Market: Company Share Analysis, 2020 (%)
Figure 12 Celgene Corporation: Key Financials
Figure 13 Celgene Corporation: Segmental Revenue
Figure 14 Celgene Corporation: Geographical Revenue
Figure 15 Janssen Biotech, Inc.: Key Financials
Figure 16 Janssen Biotech, Inc.: Segmental Revenue
Figure 17 Janssen Biotech, Inc.: Geographical Revenue
Figure 18 Bristol-Myers Squibb Company: Key Financials
Figure 19 Bristol-Myers Squibb Company: Segmental Revenue
Figure 20 Bristol-Myers Squibb Company: Geographical Revenue
Figure 21 Novartis AG: Key Financials
Figure 22 Novartis AG: Segmental Revenue
Figure 23 Novartis AG: Geographical Revenue
Figure 24 Millennium Pharmaceuticals: Key Financials
Figure 25 Millennium Pharmaceuticals: Segmental Revenue
Figure 26 Millennium Pharmaceuticals. Geographical Revenue
Figure 27 Amgen, Inc: Key Financials
Figure 28 Amgen, Inc: Segmental Revenue
Figure 29 Amgen, Inc: Geographical Revenue
Figure 30 Genzyme Corporation: Key Financials
Figure 31 Genzyme Corporation: Segmental Revenue
Figure 32 Genzyme Corporation: Geographical Revenue
Figure 33 Juno Therapeutics: Key Financials
Figure 34 Juno Therapeutics: Segmental Revenue
Figure 35 Juno Therapeutics: Geographical Revenue
Figure 36 Johnson & Johnson: Key Financials
Figure 37 Johnson & Johnson: Segmental Revenue
Figure 38 Johnson & Johnson: Geographical Revenue
Figure 39 F. Hoffmann-La Roche Ltd: Key Financials
Figure 40 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 41 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 42 GlaxoSmithKline plc: Key Financials
Figure 43 GlaxoSmithKline plc: Segmental Revenue
Figure 44 GlaxoSmithKline plc: Geographical Revenue
Figure 45 AbbVie Inc: Key Financials
Figure 46 AbbVie Inc: Segmental Revenue
Figure 47 AbbVie Inc: Geographical Revenue
Figure 48 Innate Pharma SA: Key Financials
Figure 49 Innate Pharma SA: Segmental Revenue
Figure 50 Innate Pharma SA: Geographical Revenue
Figure 51 Celldex Therapeutics, Inc: Key Financials
Figure 52 Celldex Therapeutics, Inc: Segmental Revenue
Figure 53 Celldex Therapeutics, Inc: Geographical Revenue
Figure 54 BrainScope Company, Inc, Inc: Key Financials
Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue
Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue
Figure 57 Pfizer, Inc: Key Financials
Figure 58 Pfizer, Inc: Segmental Revenue
Figure 59 Pfizer, Inc: Geographical Revenue
Figure 60 Takeda Pharmaceuticals, Inc: Key Financials
Figure 61 Takeda Pharmaceuticals, Inc: Segmental Revenue
Figure 62 Takeda Pharmaceuticals, Inc: Geographical Revenue
Figure 63 Onyx Pharmaceuticals: Key Financials
Figure 64 Onyx Pharmaceuticals: Segmental Revenue
Figure 65 Onyx Pharmaceuticals: Geographical Revenue
Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials
Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue
Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue
Figure 69 Stemedica Cell Technologies Inc: Key Financials
Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue
Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue
Figure 72 Banayan Biomarkers Inc: Key Financials
Figure 73 Banayan Biomarkers Inc: Segmental Revenue
Figure 74 Banayan Biomarkers Inc: Geographical Revenue
Figure 75 Vasopharm GmbH: Key Financials
Figure 76 Vasopharm GmbH: Segmental Revenue
Figure 77 Vasopharm GmbH: Geographical Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
